Invivyd stock maintains Buy rating at BTIG, $10 target
BTIG maintained a Buy rating and $10.00 price target on Invivyd Inc. (NASDAQ:IVVD), citing upcoming immunogenicity data from the DECLARATION trial. The stock is trading at $0.56, down 76% year-to-date. The company reported positive results from the LIBERTY trial for VYD2311, with strong safety and tolerability compared to an mRNA vaccine. Invivyd has a 92% gross profit margin but is burning through cash quickly.
How this was made
The 30-second read
Why it matters
The main tradable element is sentiment around an upcoming immunogenicity dataset and the FDA-refined Accelerated Approval framework, but the lack of a specific date and absence of a new event update reduce immediacy.
Market read
Traders may use this as a sentiment and catalyst-timing check for IVVD, but it is not a fresh clinical outcome or regulatory decision.
What to watch
Cash burn is highlighted as a critical consideration, which can dominate valuation even if trial data timing improves; also, the FDA timing refinement is process-related rather than a confirmed clinical outcome.
Background
Invivyd is developing VYD2311 and running the expanded Phase 3 DECLARATION confirmatory trial, with an Accelerated Approval approach discussed with the FDA.
Ticker impact
BTIG maintained a Buy on Invivyd and reiterated a $10 target, citing imminent immunogenicity data from the DECLARATION trial and FDA dialogue on VYD2311’s Accelerated Approval path.
Likely modest support for the stock as traders price in the near-term possibility of confirmatory-conversion evidence, tempered by the lack of a specific data date.
The piece is primarily an analyst stance, but it adds a concrete timing refinement (FDA dialogue) and reiterates the $10 target, which can influence near-term sentiment around trial catalysts.
Market effects
Reinforces investor focus on COVID-era monoclonal antibody development and Accelerated Approval conversion pathways for biotech trial programs.
Limited, single-name biotech sentiment with no clear broader regional catalyst.
Low, as the story is company-specific and tied to US FDA process and trial execution.
Counterpoint
The article provides no new trial event update and no specific immunogenicity data date, so the catalyst may slip and the stock’s extreme YTD drawdown could reflect deeper execution or financing risk.
Key entities
- companyInvivyd Inc.
NASDAQ-listed biotech developing VYD2311 and running the DECLARATION trial; subject of the analyst rating and trial-timing commentary.
- analyst_firmBTIG
Maintained a Buy rating and $10 price target, citing imminent immunogenicity data and FDA dialogue.
- regulatorFDA
Dialogue with the FDA refined details of the Accelerated Approval approach for VYD2311.

